Neuphoria Therapeutics Inc.
NEUP
$4.19
-$0.18-4.12%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 12.50% | 97.61% | 132.19% | 60.09% | 49.32% |
| Total Depreciation and Amortization | 0.02% | -0.03% | -20.03% | -33.33% | -20.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 274.20% | 121.49% | -2,754.58% | -168.75% | -628.79% |
| Change in Net Operating Assets | 907.78% | -134.15% | -94.12% | -107.69% | -105.09% |
| Cash from Operations | 104.87% | 100.53% | 104.07% | 17.05% | 8.29% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 24.18% | -84.88% | -72.45% | -45.62% | -61.38% |
| Repurchase of Common Stock | -- | -- | 99.93% | 99.96% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -97.81% | -100.00% | 1,352.40% | 708.94% | 292.35% |
| Cash from Financing | -64.89% | -89.88% | 0.13% | 39.41% | 482.17% |
| Foreign Exchange rate Adjustments | -143.90% | -104.81% | 116.41% | -389.88% | 193.05% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 11,911.68% | 217.25% | 204.61% | 47.37% | 99.66% |